Cases of adverse reaction to psychotropic drugs and possible association with pharmacogenetics

1Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Thousands of samples for pharmacogenetic tests have been analysed in our laboratory since its establishment. In this article we describe some of the most interesting cases of CYP poor metabolisers associated with adverse reactions to psychotropic drugs. Prevention of disease/illness, including Adverse Drug Reaction (ADR), is an aim of modern medicine. Scientific data supports the fact that evaluation of drug toxicology includes several factors, one of which is genetic variations in pharmacodynamics and pharmacokinetics of drug pathways. These variations are only a part of toxicity evaluation, however, even if it would help to prevent only a small percentage of patients from suffering adverse drug reactions, especially life threatening ADRs, pharmacogenetic testing should play a significant role in any modern psychopharmacologic practice. Medical practitioners should also consider the use of other medications or alternative dosing strategies for drugs in patients identified as altered metabolisers. This will promise not only better and safer treatments for patients, but also potentially lowering overall healthcare costs. ©2012 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Piatkov, I., Jones, T., & McLean, M. (2012). Cases of adverse reaction to psychotropic drugs and possible association with pharmacogenetics. Journal of Personalized Medicine, 2(4), 149–157. https://doi.org/10.3390/jpm2040149

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free